Forma Therapeutics, Tgen deal

Forma and the institute's TGen Drug Development (TD2) cancer drug development subsidiary partnered to jointly develop small molecule cancer therapies. The partners said TD2 will bring to Forma its preclinical and clinical development capabilities. As part of the deal, Stephen Gately, TD2's president and CSO, and Daniel Von Hoff, the institute's distinguished professor and physician-in-chief, will serve as clinical advisors to Forma. Details were not disclosed. ...